The Impact of COVID-19 Third Dose Vaccination on the Magnitude of Antigen Specific T Cells in Kidney Transplant Patients
-
Published:2024-08-31
Issue:
Volume:
Page:655-664
-
ISSN:1802-9973
-
Container-title:Physiological Research
-
language:en
-
Short-container-title:Physiol Res
Author:
Girmanova E, Duskova J, Mrazova P, Fialova M, Viklicky O, Hruba P1
Affiliation:
1. Transplant Laboratory, Institute for Clinical and Experimental Medicine, Prague, Czech Republic. petra.hruba@ikem.cz
Abstract
Measuring T cell response can add information about antivirus immunity provided by antibody test results. The study evaluates the impact of a third mRNA COVID-19 vaccine dose on T cell response and antibody production in kidney transplant recipients (25 KTRs) versus healthy controls (26 Hc). Results show a significant rise in S-activated CD4+CD154+IFNγ+TNFα+ double producer cells in both KTRs (p=0.025) and Hc (p=0.009) as well as increased spike antibody response in KTRs (p=0.00019) and Hc (p=3.10-8) third-month post-third dose. Moreover, the study revealed a drop in seronegative KTRs (non-responders) from 9/25 (36%) pre-third dose to 2/25 (7%) at 3 months post-third dose while 5/9 (56%) of non-responders post-second dose showed specific T cell responses. Notably, the third dose significantly improved seroconversion rates in both KTRs and Hc, although Hc individuals exhibited higher antibody levels.
Publisher
Institute of Physiology of the Czech Academy of Sciences
Reference23 articles.
1. Grupper A, Rabinowich L, Ben-Yehoyada M, Katchman E, Baruch R, Freund T, Hagin D, Shlomo SB, Schwartz D, Schwartz IF, Shashar M, Bassat OK, Halperin T, Turner D, Saiag E, Goykhman Y, Shibolet O, Levy S, Houri I, Katchman H. Humoral Response to the Third Dose of Sars-Cov-2 Vaccine in Kidney Transplant Recipients. Transplant Proc 2022;54:1439-1445. https://doi.org/10.1016/j.transproceed.2022.02.011 2. Le Bert N, Tan AT, Kunasegaran K, Tham CYL, Hafezi M, Chia A, Chng MHY, Lin M, Tan N, Linster M, Chia WN, Chen MIC, Wang L-F, Ooi EE, Kalimuddin S, Tambyah PA, Low JG-H, Tan Y-J, Bertoletti A. SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls. Nature 2020;584:457-462. https://doi.org/10.1038/s41586-020-2550-z 3. Pross V, Sattler A, Lukassen S, Toth L, Thole LML, Siegle J, Stahl C, He A, Damm G, Seehofer D, Gotz C, Bayerl C, Jager P, Macke A, Eggeling S, Kirzinger B, Mayr T, Herbst H, Beyer K, Laue D, Kronke J, Braune J, Rosseck F, Kittner B, Friedersdorff F, Hubatsch M, Weinberger S, Lachmann N, Hofmann VM, Schrezenmeier E, Ludwig C, Schrezenmeier H, Jechow K, Conrad C, Kotsch K. SARS-CoV-2 mRNA vaccination-induced immunological memory in human nonlymphoid and lymphoid tissues. J Clin Invest 2023;133. https://doi.org/10.1172/JCI171797 4. Taheri S. Efficacy and safety of booster vaccination against SARS-CoV-2 in dialysis and renal transplant patients: systematic review and meta-analysis. Int Urol Nephrol 2023;55:791-802. https://doi.org/10.1007/s11255-023-03471-x 5. Performance characteristics of five immunoassays for SARS-CoV-2: a head-to-head benchmark comparison. Lancet Infect Dis 2020;20:1390-1400. https://doi.org/10.1016/S1473-3099(20)30634-4
|
|